Rare diseases
Investigational molecules
Locations
Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients
AustriaStudy of Lenvatinib, Pembrolizumab, and Chemotherapy Combination for Patients with Advanced Esophageal Cancer Previously Treated with PD-1/PD-L1 Therapy
GermanyContinued Cancer Treatment Study with Abiraterone, Ipatasertib, Tiragolumab, and Drug Combination for Patients from Previous Genentech/Roche Trials
BelgiumEffect of a multidisciplinary care pathway on safety of oral anticancer therapy in patients aged ≥70 with cancer (capecitabine and drug combination)
FranceAdvanced hepatocellular carcinoma patients: assessing atezolizumab drug combination and other treatment sequences
ItalyStudy of Sodium Valproate and Lenvatinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
ItalyPhase 2 Study of Durvalumab + Tremelimumab with Lenvatinib vs Durvalumab + Tremelimumab Alone in Patients with Unresectable Hepatocellular Carcinoma
ItalyA study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer
SpainA study of pembrolizumab and lenvatinib for patients with high risk locally advanced cervical cancer after chemoradiotherapy and brachytherapy
The NetherlandsStudy of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab
AustriaA study comparing how lenvatinib capsules are absorbed in the body in healthy volunteers under fasting and fed conditions
PortugalStudy of Pembrolizumab and Lenvatinib for Patients with Classic Kaposi Sarcoma After Previous Treatment
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
